CR13626: A Promising Oral Multi-Kinase Inhibitor for Glioblastoma Treatment in Mice

3 June 2024
The abstract discusses the development of a new drug candidate, CR13626, for glioblastoma, a severe brain cancer with no cure. The drug targets tyrosine kinases (TKs), particularly receptor tyrosine kinases (RTKs) like EGFR and KDR, which are significant in tumor growth and blood vessel formation. The study evaluates CR13626's ability to penetrate the blood-brain barrier and its efficacy against GBM in both in vitro and in vivo tests.

CR13626 was tested against 173 kinase enzymes and showed potent inhibition of TKs associated with GBM, with IC50 values in the nanomolar range. The drug was effective in reducing the proliferation of various human GBM cell lines and demonstrated a significant reduction in tumor growth in an orthotopic mouse model, leading to an increase in the median survival rate of the treated animals.

Pharmacokinetic studies revealed that CR13626 has good oral bioavailability and can cross into the brain, with a brain/plasma ratio of 1.4. The drug's ability to penetrate the blood-brain barrier and inhibit multiple TKs, coupled with its impact on reducing tumor growth and extending survival in mice, supports its potential as a drug candidate for glioblastoma treatment.

The research was presented at the American Association for Cancer Research Annual Meeting in 2020, with Chiara Galimberti and colleagues as authors.

How to Use Synapse Database to Search and Analyze Translational Medicine Data?

The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

图片包含 应用程序

描述已自动生成

Click on the image below to go directly to the Translational Medicine search interface.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成